Edition:
United Kingdom

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

12.61USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$12.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
139,073
52-wk High
$27.06
52-wk Low
$3.61

Latest Key Developments (Source: Significant Developments)

Galmed Pharmaceuticals Q2 Loss Per Share $0.17
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Galmed Pharmaceuticals Ltd ::GALMED PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.17.Q2 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.Q2 REVENUE $300,000 VERSUS I/B/E/S VIEW $271,000.  Full Article

Galmed Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
Monday, 26 Mar 2018 

March 26 (Reuters) - Galmed Pharmaceuticals Ltd ::GALMED PHARMACEUTICALS LTD FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Galmed Pharmaceuticals Q4 Loss Per Share $0.27
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Galmed Pharmaceuticals Ltd ::GALMED PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 REVENUE $300,000 VERSUS I/B/E/S VIEW $289,000.Q4 LOSS PER SHARE $0.27.  Full Article

683 Capital Management Llc Reports 5.1 Pct Passive Stake In Galmed Pharmaceuticals Ltd As Of Dec 6
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Galmed Pharmaceuticals Ltd ::683 CAPITAL MANAGEMENT LLC REPORTS 5.1 PERCENT PASSIVE STAKE IN GALMED PHARMACEUTICALS LTD AS OF DEC 6 - SEC FILING.  Full Article

Galmed Pharmaceuticals Q3 loss per share $0.23
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.23.Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Q3 revenue $300,000 versus I/B/E/S view $319,000.Galmed Pharmaceuticals - ‍cash, cash equivalents,marketable securities totaled $9.0 million as of Sept 30, compared to $15.5 million at December 31, 2016​.Galmed Pharmaceuticals Ltd - ‍Galmed believes that its cash balance will be sufficient to maintain its current operations through 2018​.  Full Article

Israeli company Galmed gets positive trial results for liver drug

TEL AVIV, June 12 Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for NASH, a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.